Medulloblastoma:_freedom_from_relapse_longer_than_8_years--a_therapeutic_cure?_Seventy-seven_patients_presenting_with_medulloblastoma_between_1958_and_1986_were_treated_at_Stanford_University_Medical_Center_and_studied_retrospectively._Multimodality_therapy_utilized_surgical_extirpation_followed_by_megavoltage_irradiation._In_15_cases_chemotherapy_was_used_as_adjunctive_treatment._The_10-_and_15-year_actuarial_survival_rates_were_both_41%_with_an_18-year_maximum_follow-up_period_(median_4.75_years)._There_were_no_treatment_failures_after_8_years_of_tumor-free_survival._Gross_total_removal_of_tumor_was_achieved_in_22_patients_(32%);_the_surgical_mortality_rate_was_3.9%._No_significant_difference_was_noted_in_the_incidence_of_metastatic_disease_between_shunted_and_nonshunted_patients._The_classical_form_of_medulloblastoma_was_present_in_67%_of_cases_while_the_desmoplastic_subtype_was_found_in_16%._Survival_rates_were_best_for_patients_presenting_after_1970,_for_those_with_desmoplastic_tumors,_and_for_patients_receiving_high-dose_irradiation_(greater_than_or_equal_to_5000_cGy)_to_the_posterior_fossa._Although_early_data_on_freedom_from_relapse_suggested_a_possible_beneficial_effect_from_chemotherapy,_long-term_follow-up_results_showed_no_advantage_from_this_modality_of_treatment._The_patterns_of_relapse_and_survival_were_examined;_64%_of_relapses_occurred_within_the_central_nervous_system,_and_Collins'_rule_was_applicable_in_83%_of_cases_beyond_the_period_of_risk._Although_patients_treated_for_recurrent_disease_could_be_palliated,_none_were_long-term_survivors._The_study_data_indicate_that_freedom_from_relapse_beyond_8_years_from_diagnosis_can_be_considered_as_a_cure_in_this_disease._Long-term_follow-up_monitoring_is_essential_to_determine_efficacy_of_treatment_and_to_assess_survival_patterns_accurately.